Rapid Determination of Kinetic Constants for Slow-Binding Inhibitors and Inactivators of Human Histone Deacetylase 8.
Aleksandra KopranovicFranz-Josef Meyer-AlmesPublished in: International journal of molecular sciences (2024)
The kinetics and mechanism of drug binding to its target are critical to pharmacological efficacy. A high throughput (HTS) screen often results in hundreds of hits, of which usually only simple IC 50 values are determined during reconfirmation. However, kinetic parameters such as residence time for reversible inhibitors and the k inact / K I ratio, which is the critical measure for evaluating covalent inactivators, are early predictive measures to assess the chances of success of the hits in the clinic. Using the promising cancer target human histone deacetylase 8 as an example, we present a robust method that calculates concentration-dependent apparent rate constants for the inhibition or inactivation of HDAC8 from dose-response curves recorded after different pre-incubation times. With these data, hit compounds can be classified according to their mechanism of action, and the relevant kinetic parameters can be calculated in a highly parallel fashion. HDAC8 inhibitors with known modes of action were correctly assigned to their mechanism, and the binding mechanisms of some hits from an internal HDAC8 screening campaign were newly determined. The oxonitriles SVE04 and SVE27 were classified as fast reversible HDAC8 inhibitors with moderate time-constant IC 50 values of 4.2 and 2.6 µM, respectively. The hit compound TJ-19-24 and SAH03 behave like slow two-step inactivators or reversible inhibitors, with a very low reverse isomerization rate.
Keyphrases
- histone deacetylase
- high throughput
- endothelial cells
- magnetic resonance imaging
- emergency department
- electronic health record
- mass spectrometry
- induced pluripotent stem cells
- transcription factor
- magnetic resonance
- binding protein
- deep learning
- artificial intelligence
- computed tomography
- young adults
- squamous cell
- liquid chromatography
- tandem mass spectrometry
- adverse drug
- childhood cancer